¶ Ridgeback Biotherapeutics
.png)
This page has moved! Click here to view the most up-to-date version of this page on the White Rose Wiki.
Ridgeback Biotherapeutics is an American biotechnology company based in Miami, Florida.[1]
¶ COVID-19
Ridgeback collaborated with Merck to develop molnupiravir, an oral mutagenic anti-viral compound, to treat COVID-19. In October 2021, the two companies reported that data from their Phase 3 clinical trial showed molnupiravir “cuts the risk of hospitalization and death from COVID-19 by 50% in people who have mild to moderate forms of the disease.”[1:1][2]
In January 2022, Ridgeback and Merck announced they would supply UNICEF with 3 million doses of molnupiravir through the Access to COVID-19 Tools Accelerator (ACT-Accelerator) Therapeutics Partnership.[3]
¶ Organization
Ridgeback is a member of the Medical CBRN Defense Consortium.[4]
¶ External links
Moody, M., Ryan, P., Dannenbaum, P., Kruper, R., & Carvalho, C. (2021, October 1). Merck and Ridgeback’s Investigational Oral Antiviral Molnupiravir Reduced the Risk of Hospitalization or Death by Approximately 50 Percent Compared to Placebo for Patients with Mild or Moderate COVID-19 in Positive Interim Analysis of Phase 3 Study. Merck. Retrieved December 5, 2021, from https://archive.ph/Ov4Cg ↩︎ ↩︎
Halford, B., Howes, L., & Satyanarayana, M. (2021, October 1). Molnupiravir reduces risk of hospitalization and death in patients with mild to moderate COVID-19. Chemical & Engineering News; American Chemical Society. https://archive.ph/8sJfE ↩︎
Linnane, C. (2022, January 18). Merck and Ridgeback Biotherapeutics to supply 3 million doses of COVID antiviral to Unicef in 2022. MarketWatch. https://archive.ph/ZbutW ↩︎
Current Members. MCDC. Retrieved January 3, 2023, from http://archive.today/2023.01.03-195328/https://www.medcbrn.org/current-members/ ↩︎